La cadena de opciones muestra datos clave de las opciones de acciones de Intellia Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Intellia Therapeutics..

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Cadena de Opciones

INTELLIA THERAPEUTICS INC

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

ASML

CLSK

CRWD

ETNB

FORM

GPRE

INTC

NBTX

NTLA

ORBS

RGTI

SNPS

Radian Group e Intel lideraron las alzas en Wall Street tras anuncios de adquisiciones y alianzas estratégicas que impulsaron al Nasdaq.

Radian Group, Intel, Nanobiotix, CrowdStrike y otras acciones de EE.UU. que suben el jueves

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Health Care

Press Releases

General

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Legal

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Earnings

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Small Cap

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Cidara Therapeutics

Celcuity

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

GRAIL

IDEAYA Biosciences

Immunovant

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

JMP Securities

HC Wainwright & Co.

Guggenheim

Chardan Capital

RBC Capital

Comments

Intellia Therapeutics

Intellia Therapeutics (NTLA) Opciones

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL